Corticosteroid R&D for IBD

Despite the availability of novel therapeutic strategies for inflammatory bowel disease (IBD) as well, including biological therapies and small molecules, corticosteroids continue to play a major role in induction of IBD. They quickly became a major treatment for IBD as this drug could be taken orally and topically or injection into the veins. These medications are effective for a need basis to manage acute episodes (flares) of IBD, and they can help most patients experience rapid symptom relief in those with moderate-to-severe activity disease. Corticosteroids are reluctant to take as long-term therapy because of their known side effects and they generally fail in achieving control over IBD. Thus, there is a need to generate corticosteroids with fewer systemic side effects for the management of IBD.

Fig. 1. Glucocorticoids influence both the innate and adaptive immune responses. Fig. 1. Glucocorticoid effects in innate and adaptive immune response. (Bruscoli et al., 2021)

Corticosteroid R&D Services

Through our research in IBD knowledge and advancement, Ace Therapeutics, an IBD-oriented CRO, dedicates to developing and Optimizing corticosteroids for our client to support searching for novel therapeutics for IBD. Our devoted experts would provide our clients with the in-house resources and knowledge in a comprehensive and efficient way.

Development of Novel Corticosteroids for IBD

Leveraging our highly skilled team of specialists and our cutting-edge technologies for experimental operations, Ace Therapeutics is able to provide the design and synthesis of novel corticosteroids that achieve high potency and low bioavailability based on customer request. Our service provides full-process treatment, including the concept and synthesis of corticosteroids, as well as the screening of drug efficacy and safety through a series of animal experiments.

Development of Drug Delivery Systems for IBD Therapy

We work with our customers to derive novel delivery systems for corticosteroid drugs which enhances the pharmacological efficacy of the drug. This depict how targeted drug delivery systems can regulate solubility, drug's aggregation, low bioavailability, poor biodistribution and minimise side effects.

Drug-Delivery Systems	Details
Erythrocytes as drug carriers	We can help the customer to design a biotechnology that will use erythrocytes for highly specific delivery of corticosteroids. Erythrocytes are activated to catalyse the prodrugs in their bioactive form
Colon-targeted delivery systems	We design colon-targeted drug-delivery vehicles capable of delivering sustained release of corticosteroids to the colon.
Nanoparticles (NPs)	Based on manipulation of the particle size, the migratory capability of the drug in mucus can be enhanced and its half-life can be prolonged. Further regulation can also be exerted on its interaction with the colonic mucosa by tinkering with the nanoparticle surface charge, which can increase the efficacy of the system.
Polymeric micelles	By attaching polyethylene glycol (PEG) to the outer surface of nanoparticles, we prolong circulation time- and slow -steroid release.

Welcome to Ace Therapeutics, where we always strive for excellence and innovation in the field of IBD drug development. If you are looking for a one-stop shop for IBD corticosteroid drug development, we are your best partner. If you're interested in our services, please contact us.

Reference

Bruscoli, S., et al. (2021). Glucocorticoid therapy in inflammatory bowel disease: mechanisms and clinical practice. Frontiers in immunology, 12, 691480.

! For research use only, not intended for any clinical use.